Ocuphire Pharma
secondary of subjects non study eye returning to | Ocuphire Pharma
Company
Deck Type
Deck date
March 2021
Slide
14 of 29
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2022
mean pupil diameter over time by eye color | Ocuphire Pharma
Results
March 2022
mean pupil diameter over time by mydriatic agents | Ocuphire Pharma
Results
March 2022
mean pupil diameter over time | Ocuphire Pharma
Results
March 2022
comparison of one drop fellow eye with two drops study eye | Ocuphire Pharma
Related slides by other companies
ATAI
Investor Presentation
October 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Chimerix
Investor Presentation
March 2023
pivotal phase action trial design primary overall survival day | Chimerix
ATAI
Investor Presentation
November 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
ATAI
Investor Presentation
September 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights